These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 6652672)

  • 1. [The effect of hemoperfusion through activated charcoal on middle molecular substances in the plasma during a long-term dialysis program].
    Mydlík M; Dzúrik R; Derzsiová K; Spustová V
    Cas Lek Cesk; 1983 Dec; 122(51):1573-6. PubMed ID: 6652672
    [No Abstract]   [Full Text] [Related]  

  • 2. [Can the concentration of middle molecular substances in plasma contribute to the assessment of the adequacy of regular dialysis therapy?].
    Válek A; Spustová V; Lopot F; Erben J; Dzúrik R
    Cas Lek Cesk; 1984 May; 123(20):599-604. PubMed ID: 6467309
    [No Abstract]   [Full Text] [Related]  

  • 3. [The evaluation of the efficacy of efferent therapy in patients with acute and chronic kidney failure by the spectrum of blood middle-molecule fractions].
    Kon'kova TA; Chudnovskaia MV; Golovanov SA
    Urol Nefrol (Mosk); 1994; (4):35-7. PubMed ID: 7985299
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term hemoperfusion with coated activated charcoal.
    Mamdani B; Dunea G; Siemsen AW
    Clin Toxicol; 1980 Nov; 17(4):543-6. PubMed ID: 7460506
    [No Abstract]   [Full Text] [Related]  

  • 5. Comparative studies on the effect of hemoperfusion and hemodialysis on the elimination of some uremic toxins.
    Trznadel K; Walasek L; Kidawa Z; Lutz W
    Clin Nephrol; 1978 Dec; 10(6):229-31. PubMed ID: 729215
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Hemosorption as a treatment method for uremic complications].
    Pilotovich VS; Ostapenko VA; Shilaĭ LM; Kirkovskiĭ VV; Nikolaĭchik VV
    Klin Med (Mosk); 1982 Apr; 60(4):77-80. PubMed ID: 7098397
    [No Abstract]   [Full Text] [Related]  

  • 7. A purification method by uncoated charcoal.
    Cerulli N; Politi L; D'Angelo AR; Scandurra R
    Adv Exp Med Biol; 1987; 223():193-6. PubMed ID: 3447435
    [No Abstract]   [Full Text] [Related]  

  • 8. Concentration of plasma middle molecular weight substances and clinical condition of patients undergoing short-time regular dialysis treatment.
    Válek A; Dzúrik R; Spustová V; Válková D
    Artif Organs; 1981; 4 Suppl():173-6. PubMed ID: 7295088
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Use of hemosorption and hemodialysis in the treatment of chronic renal failure].
    Riabov SI; Shostka GD; Lukichev BG; Strelko VV; Spiridonov VN
    Ter Arkh; 1981; 53(6):15-21. PubMed ID: 7281026
    [No Abstract]   [Full Text] [Related]  

  • 10. Haemoperfusion in the management of end-stage renal disease.
    Winchester JF
    Life Support Syst; 1984; 2(2):107-11. PubMed ID: 6384670
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Hemofiltration and hemoperfusion performed in series for the purpose of removing beta 2 microglobulin].
    Marangoni R; Civardi F; Savino R; Manfredi A; Masi F; Avanzi C; Lino S
    Cas Lek Cesk; 1989 Sep; 128(39):1217-20. PubMed ID: 2684408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Use of enterodesis in the complex treatment of patients with pronounced chronic renal failure].
    Del'machinskiĭ BV; Ermolenko VM; Lifshits NL; Suzdaleva VV; Makarova NL
    Ter Arkh; 1988; 60(8):89-91. PubMed ID: 3227485
    [No Abstract]   [Full Text] [Related]  

  • 13. [The anticoagulant activity of the plasma ultrafiltrate as a possible criterion of uremic poisoning].
    Sukhanov VA; Chuzhinov SV; Koriakov IO; Zlokazov VB
    Ter Arkh; 1991; 63(6):68-71. PubMed ID: 1948752
    [No Abstract]   [Full Text] [Related]  

  • 14. [Activated charcoal surface ultrastructure after haemoperfusion (author's transl)].
    Bucek J; Mydlík M
    Cas Lek Cesk; 1980 Nov; 119(45):1205-7. PubMed ID: 7438181
    [No Abstract]   [Full Text] [Related]  

  • 15. [Clinical results of charcoal hemoperfusion: studies of 55 cases extending over 250 incidents].
    Agishi T; Yamashita N; Ota K
    Nihon Rinsho; 1980 Dec; 38(12):4697-702. PubMed ID: 7253246
    [No Abstract]   [Full Text] [Related]  

  • 16. [A comparison of the efficiency of eliminating middle-weight molecules and myoinositol from plasma during hemoperfusion and hemodialysis in cases of chronic uremia].
    Trznadel K; Kidawa Z; Walasek L; Lutz W
    Pol Tyg Lek; 1978 Feb; 33(7):257-9. PubMed ID: 758030
    [No Abstract]   [Full Text] [Related]  

  • 17. [Current concepts of hemoperfusion through activated charcoal in the treatment of internal diseases].
    Dmitriev AA
    Ter Arkh; 1983; 55(6):140-8. PubMed ID: 6351328
    [No Abstract]   [Full Text] [Related]  

  • 18. Dialysis therapy: 'think differently'.
    Perrone B
    Nephrol Dial Transplant; 2007 Jul; 22 Suppl 5():v1-2. PubMed ID: 17586840
    [No Abstract]   [Full Text] [Related]  

  • 19. New biological method for determination of the desintoxication rate of human plasma after dialysis.
    Kovatchev D; Dimitrov H; Hristova P; Nenov D
    Life Support Syst; 1983; 1 Suppl 1():191-4. PubMed ID: 6336408
    [No Abstract]   [Full Text] [Related]  

  • 20. Effect of blood purification on plasma levels of intact parathyroid hormone in patients with chronic renal failure.
    Liu J; Liu ZQ; Tao HQ
    Di Yi Jun Yi Da Xue Xue Bao; 2004 Feb; 24(2):234-5. PubMed ID: 14965840
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.